A few decades ago, a diagnosis of spinal muscular atrophy in an infant was effectively a sentence. Parents were told their child would likely never sit, never walk, and in the most severe cases, would not survive past the age of two. There was no treatment. There was no plan. There was only grief, arranged in stages.
Then researchers identified a single gene — SMN1 — and the protein it produces, called simply SMN. That discovery did not just open a door. It rewrote what was possible for thousands of families.
What SMN Actually Does
The Survival Motor Neuron protein, or SMN, is not glamorous. It does not make headlines on its own. Inside every cell of the human body, SMN helps assemble the molecular machinery responsible for processing RNA — the intermediate instructions that tell cells which proteins to build. Without enough SMN, cells cannot properly splice and prepare these instructions, and they begin to malfunction.
Most cells can tolerate a partial shortage of SMN. Motor neurons cannot. These are the nerve cells that connect the spinal cord to muscles, commanding movement, breathing, and swallowing. When SMN levels drop too low, motor neurons degenerate and die. Muscles receive no signal. They waste away. This cascade of loss is what we call spinal muscular atrophy, or SMA.
The severity depends on how much SMN protein is present. People have two genes that can produce it: SMN1, which makes the full, functional protein, and SMN2, a near-identical backup copy that mostly produces a truncated, unstable version. SMN2 generates only about 10 percent of the functional protein that SMN1 does. Most people have two copies of SMN1, one from each parent. In individuals with SMA, both copies of SMN1 are missing or defective. The number of SMN2 copies they carry becomes the primary factor in how mild or severe their disease will be.
This is not abstract genetics. This is the difference between a child who never lifts their head and a child who walks into kindergarten.
The Diagnostic Shift
Before the SMN gene was mapped to chromosome 5 in 1995, SMA was diagnosed by its symptoms and by muscle biopsies. Clinicians classified it into types based on age of onset and motor milestones never achieved. Type 1, formerly called Werdnig-Hoffmann disease, was the most severe. Type 4, the mildest, appeared in adulthood. These labels described what was happening but could not explain why.
The identification of SMN1 changed that. For the first time, a blood test could confirm SMA with certainty. Genetic counseling could inform carrier status in prospective parents. And researchers had a concrete target — not a vague category of neurodegeneration, but a specific protein whose absence set the entire disease in motion.
That target made everything else possible.
From Target to Treatment
For years after the gene was discovered, families waited. Knowing the cause of SMA is not the same as having a cure, and the gap between knowledge and therapy can be agonizing. But the clarity of the target — a missing or deficient protein — focused the research community in a way that few diseases enjoy.
The first major breakthrough came from a surprisingly simple observation: SMN2 produces some functional SMN protein. Not much, but some. If that production could be increased — if the backup gene could be coaxed into doing more — it might partially compensate for the loss of SMN1.
This logic led to the development of nusinersen, approved in 2016. Delivered by injection into the spinal fluid, nusinersen increases SMN protein production from SMN2. Clinical trials showed infants gaining motor functions that had never been seen in untreated SMA Type 1. Children who would have lost the ability to swallow were feeding. Children who would never have sat were reaching for toys.
A second approach took a more direct route: gene replacement therapy. Onasemnogene abeparvovec, approved in 2019, delivers a functional copy of SMN1 directly into motor neurons using a viral vector. Administered as a single intravenous infusion, often to infants just weeks old, it aims to restore SMN production at its source. The results in early-treated children have been remarkable — walking, talking, and meeting developmental milestones that the natural history of SMA would have made impossible.
A third approach, risdiplam, works as an oral medication that also boosts SMN2 output but through a different mechanism than nusinersen. Approved in 2020, it offered families a treatment that did not require spinal injections, broadening access and convenience.
Three treatments in four years. For a disease that had none for decades. This pace is almost unheard of in rare disease drug development, and it traces directly back to the precision of the target.
The Window That Cannot Be Missed
These treatments share one critical limitation: they work best early. Motor neurons, once lost, do not regenerate. If SMN protein is restored before extensive neuron death, the outcome is dramatically better than if treatment begins after significant damage has accumulated.
This reality has driven one of the most significant shifts in pediatric medicine: the push for newborn screening for SMA. In the United States, a growing number of states now include SMA on their newborn screening panels. The logic is straightforward. A child born with SMA appears healthy at birth. Symptoms may not appear for weeks or months, and by then, motor neurons are already dying. A genetic test on the standard newborn blood spot can identify SMA before symptoms begin, allowing treatment to start in that critical early window.
Countries that have implemented newborn screening for SMA have already documented substantially better outcomes compared to children diagnosed symptomatically. The difference is not marginal. It is the difference between a child who walks and a child who never will.
Not every country screens. Not every family has access to treatment that can cost hundreds of thousands or even millions of dollars. The science has moved faster than the systems designed to deliver it, and that gap remains one of the most pressing challenges in SMA care today.
What SMN Reveals About Rare Disease
The story of the SMN protein is not just about one disease. It illustrates a model that rare disease research has long championed: when you understand the molecular basis of a condition with precision, the path to therapy becomes far more navigable than when you are treating symptoms in the dark.
SMA was once considered untreatable because it was a neurodegenerative disease, and neurodegeneration was widely assumed to be irreversible. The SMN discovery challenged that assumption. It showed that if you can intervene on the specific mechanism causing neuron death, neurons can survive. Function can be preserved. Children can develop.
This principle is now guiding research in other genetic diseases. The success of SMN-targeted therapies has provided a proof of concept that extends well beyond SMA: know the gene, understand the protein, fix the deficiency, and the body — even the nervous system — can recover in ways previously thought impossible.
There are caveats. Long-term data on treated children is still accumulating. Questions remain about durability, about whether the effects of gene therapy persist for a lifetime, about the management of children who start treatment after significant neuron loss. The treatments are not cures in the strictest sense, and families navigating SMA still face complex medical landscapes.
But the distance between the world before SMN was understood and the world after is immense. A pediatric neurologist practicing in 1990 had nothing to offer the parents of an infant with SMA beyond comfort. The same specialist practicing today has multiple therapeutic options, each grounded in the biology of a single protein.
That is what SMN means. Not just a gene, not just a protein, but a demonstration that molecular precision can transform the prognosis of a disease once defined by its hopelessness.
Survival Motor Neuron. The name itself now reads less like a technical descriptor and more like a promise that was, against considerable odds, kept.